Polysaccharide-based vaccines play a crucial role in vaccine technology. These vaccines have gained significant attention due to their ability to assist bacteria in infecting individuals, evading the immune system, and triggering inflammatory responses. They can be formulated with purified polysaccharides alone or as conjugates with carrier proteins. While vaccines containing purified polysaccharides alone stimulate B cells to produce antibodies, they do not generate immune memory responses. Utilizing a carrier protein conjugated to the polysaccharide offers several advantages. Conjugation to carrier proteins substantially enhances the immunogenicity of T cell-dependent responses to polysaccharides.
Fig.1 Interactions of polysaccharide and conjugate vaccines with follicular dendritic, B, and Tfh cells in the germinal centers. (Rappuoli, et al., 2019)
CD BioGlyco takes into account several criteria when choosing polysaccharide vaccine carriers. Safety and efficacy with a proven track record are of utmost importance. The carriers will be produced at a large scale. A thorough evaluation of physicochemical and immunological characteristics is crucial in the selection process. Following conjugation, new carriers must be assessed for their immunogenicity, reproducibility in manufacturing, appropriate exposure of reactive amino acids for conjugation, as well as solubility and stability.
It is crucial to identify the site of conjugation when using the carrier protein as the antigen. Connecting antigens to possible B-cell epitopes potentially disrupts or weaken the immune response against the carrier antigen. Hence, it is inevitable to explore and create novel carrier proteins in addition to the existing approved traditional carriers.
CD BioGlyco provides comprehensive carrier protein design services including traditional protein carrier design services, new protein carrier design services, and nanoparticle (NP) carrier design services. In addition to carrier protein design, we also provide Polysaccharide Antigen Production Services.
After years of research, CD BioGlyco has developed a complete Glyco™ Vaccine Development Platform for the Development of Carbohydrate-based vaccines. If you are interested in our services, please contact us for more details without any hesitation.
Reference:
